Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
DENTSPLY SIRONA announced that the SEC’s Division of Enforcement has concluded its investigation and does not intend to recommend any enforcement action against the company. The inquiry, initiated by the SEC in connection with an internal review led by the Audit and Finance Committee into certain financial reporting matters raised by employees, began in May 2022 and closed on October 14, 2025. The company had voluntarily contacted the SEC and fully cooperated throughout.
The closure removes a regulatory overhang tied to past financial reporting questions and reflects the regulator’s decision not to pursue action. Management characterized the outcome as a significant and favorable development.
DENTSPLY SIRONA Inc. announced that Richard C. Rosenzweig, Executive Vice President, Corporate Development, General Counsel and Secretary, will step down from that role by mutual agreement effective October 3, 2025. He will serve as a non-executive Special Legal Advisor through a Separation Date no later than March 4, 2026 to transition responsibilities. Under a Transition and Separation Agreement dated October 2, 2025, he is eligible for severance under prior agreements and will receive a monthly fixed fee of $30,000 while Special Legal Advisor; if terminated early without Cause, that amount is payable as if he served through March 4, 2026. After the Separation Date, the Company will engage him as an independent contractor for one year at $20,000 per month. Receipt of these payments is generally contingent on execution of a release and compliance with post-termination covenants. The Transition and Separation Agreement is filed as Exhibit 10.1.
Jonathan Jay Mazelsky, a director of DENTSPLY SIRONA Inc. (XRAY), was granted phantom stock units on 09/30/2025. The Form 4 reports an award of 2,386.165 phantom stock units under the directors' deferred compensation plan, with an indicated price of $12.57 per underlying share. Each phantom share is the economic equivalent of one share of common stock and becomes payable in common stock upon the reporting persons termination of service. After the reported award, the Form shows 11,620.2024 shares beneficially owned by the reporting person in a direct ownership form.
DENTSPLY SIRONA Inc. approved a one-time retention equity award to certain executives, including named executive officer Tony Johnson, Senior Vice President and Chief Supply Chain Officer. The award is a stock option grant with a grant date fair value of $2,000,000 awarded to Mr. Johnson to recognize his performance during recent CEO and CFO transitions and to incentivize retention through the next three years.
The options are expected to be granted on the second trading day after the company files its quarterly report for the fiscal quarter ended September 30, 2025, will cliff-vest on the third anniversary of the grant date provided continuous employment, and will expire on the tenth anniversary. Half of the options will have an exercise price equal to the fair market value on the grant date and half will have an exercise price equal to 110% of that value.
DENTSPLY SIRONA Inc. announced on September 8, 2025 that it completed its previously disclosed review of strategic alternatives for its Wellspect Healthcare business and the Board determined that Wellspect will remain within the Company’s portfolio. The Company furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing notes the exhibit is furnished (not "filed") and therefore is not incorporated by reference into other Securities Act or Exchange Act filings absent specific reference. No financial statements, transaction terms, or forward-looking guidance are included in the provided text.
Lazard Asset Management LLC filed a Schedule 13G reporting ownership of 10,107,657 shares of DENTSPLY SIRONA Inc. (CUSIP 24906P109), representing 5.1% of the outstanding equity as of 06/30/2025. The filer reports sole voting power over 10,002,455 shares and sole dispositive power over 10,107,657 shares. The filing identifies the reporting person as an investment adviser (IA) organized in New York and includes a certification that the securities are not held to change or influence control of the issuer. The filing is signed by Mark Anderson, Managing Director, General Counsel, dated 08/14/2025.
AQR Capital Management and its parent AQR Capital Management Holdings report a material passive stake in DENTSPLY SIRONA Inc. Together they beneficially own 13,316,771 shares of common stock, equal to 6.68% of the class. The filing shows shared voting and shared dispositive power over those shares and records no sole voting or dispositive power.
The Schedule 13G states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing lists the issuer headquarters in Charlotte, NC, gives AQR's Greenwich, CT address, and is signed by an authorized signatory on 08/14/2025. An exhibit notes AQR Capital Management, LLC is wholly owned by AQR Capital Management Holdings, LLC.
DENTSPLY SIRONA insider Daniel T. Scavilla, who serves as President, CEO and director, reported transactions dated 08/08/2025. The filing shows a disposition of 17,475.049 shares of common stock and the acquisition of 1,102,600 stock options with an exercise price of $12.96. The options are exercisable beginning 08/08/2026 and expire 08/08/2035. The grant vests in three equal annual installments, ending 08/08/2028, and is recorded with a price of $0. Ownership of the reported derivative and the disposal are shown as direct. No additional financial metrics or compensatory values are provided in the form.
Gregory T. Lucier, a director of DENTSPLY SIRONA Inc. (XRAY), reported equity awards and transfers dated 08/08/2025. The filing shows a grant of 3,858 restricted stock units (RSUs) that vest in full one year from the grant date, and a separate transfer/gift of 24,047 RSUs to a family partnership in which the reporting person disclaims beneficial ownership except for any pecuniary interest.
The report also shows an indirect holding of 21,000 shares held in the reporting person's IRA and a grant of 17,200 stock options with an exercise price of $12.96, vesting in one year and expiring on 08/08/2035. The form includes post-transaction beneficial ownership figures for the reporting person and related accounts as provided in the filing.
Andrea L. Frohning, Senior Vice President and CHRO of DENTSPLY SIRONA Inc. (ticker XRAY), reported a transaction on 08/08/2025 on Form 4. The filing shows 788 shares of common stock were withheld to cover taxes related to the vesting of restricted stock units and dividend equivalent units previously reported. The transaction is reported with code F and a price of $12.96 per share.
After the withholding, the beneficial ownership reported for Ms. Frohning is 33,252.812 shares, held directly. The Form identifies the reporting person and the issuer but does not disclose any open-market purchases or sales separate from the tax-withholding event.